Short Interest in Exicure, Inc. (NASDAQ:XCUR) Decreases By 74.8%

Exicure, Inc. (NASDAQ:XCUR) saw a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 32,600 shares, a drop of 74.8% from the August 31st total of 129,500 shares. Approximately 4.9% of the company’s stock are short sold. Based on an average daily trading volume, of 1,340,000 shares, the days-to-cover ratio is presently 0.0 days.

Insider Buying and Selling at Exicure

In other news, major shareholder Co. Ltd. Dgp purchased 237,223 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were acquired at an average price of $3.00 per share, for a total transaction of $711,669.00. Following the purchase, the insider now owns 849,223 shares in the company, valued at $2,547,669. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 3.90% of the stock is currently owned by company insiders.

Exicure Stock Performance

Shares of XCUR opened at $3.81 on Friday. The company has a market capitalization of $6.59 million, a P/E ratio of -2.51 and a beta of 1.24. The business’s 50-day moving average is $1.01 and its two-hundred day moving average is $0.41. Exicure has a fifty-two week low of $1.44 and a fifty-two week high of $6.00.

Exicure (NASDAQ:XCUR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.01) earnings per share (EPS) for the quarter.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.